NCT06069895View on ClinicalTrials.gov

Investigation of Safety, Tolerability and Pharmacokinetics of Multiple Doses of NNC0113-6856 in Healthy Participants, Including a Subset of Healthy Japanese Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

170

Participants

Timeline

Start Date

October 4, 2023

Primary Completion Date

April 23, 2025

Study Completion Date

April 23, 2025

Conditions
Healthy Participants
Interventions
DRUG

NNC0113-6856

NNC0113-6856 will be administered as oral tablets.

DRUG

Placebo

NNC0113-6856 matching placebo will be administered as oral tablets.

Trial Locations (1)

41460

Profil Institut für Stoffwechselforschung GmbH, Neuss

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY